Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy
MarketBeat
Adicet Bio (NASDAQ:ACET) expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE), Chief Executive Officer Chen Schor said at the 46th Annual Canaccord Genuity Grow
NASDAQ:ACET